nodes	percent_of_prediction	percent_of_DWPC	metapath
Bismuth Subsalicylate—PTGS2—colon cancer	0.637	1	CbGaD
Bismuth Subsalicylate—ALB—Irinotecan—colon cancer	0.0739	0.402	CbGbCtD
Bismuth Subsalicylate—ALB—Fluorouracil—colon cancer	0.0709	0.386	CbGbCtD
Bismuth Subsalicylate—ALB—Methotrexate—colon cancer	0.0391	0.213	CbGbCtD
Bismuth Subsalicylate—TF—bile—colon cancer	0.0288	0.265	CbGeAlD
Bismuth Subsalicylate—TF—blood vessel—colon cancer	0.00849	0.0783	CbGeAlD
Bismuth Subsalicylate—TF—gall bladder—colon cancer	0.00798	0.0736	CbGeAlD
Bismuth Subsalicylate—TF—embryo—colon cancer	0.00506	0.0467	CbGeAlD
Bismuth Subsalicylate—ALB—gall bladder—colon cancer	0.00415	0.0383	CbGeAlD
Bismuth Subsalicylate—TF—epithelium—colon cancer	0.00413	0.0381	CbGeAlD
Bismuth Subsalicylate—TF—renal system—colon cancer	0.00383	0.0353	CbGeAlD
Bismuth Subsalicylate—TF—lymphoid tissue—colon cancer	0.00318	0.0293	CbGeAlD
Bismuth Subsalicylate—TF—digestive system—colon cancer	0.00314	0.029	CbGeAlD
Bismuth Subsalicylate—Localized exfoliation—Capecitabine—colon cancer	0.00312	0.0481	CcSEcCtD
Bismuth Subsalicylate—TF—bone marrow—colon cancer	0.0029	0.0267	CbGeAlD
Bismuth Subsalicylate—TF—vagina—colon cancer	0.00278	0.0256	CbGeAlD
Bismuth Subsalicylate—PTGS1—endothelium—colon cancer	0.00273	0.0252	CbGeAlD
Bismuth Subsalicylate—PTGS2—endothelium—colon cancer	0.00261	0.024	CbGeAlD
Bismuth Subsalicylate—PTGS1—blood vessel—colon cancer	0.00252	0.0232	CbGeAlD
Bismuth Subsalicylate—PTGS2—blood vessel—colon cancer	0.0024	0.0222	CbGeAlD
Bismuth Subsalicylate—TF—liver—colon cancer	0.00234	0.0216	CbGeAlD
Bismuth Subsalicylate—PTGS2—gall bladder—colon cancer	0.00226	0.0209	CbGeAlD
Bismuth Subsalicylate—TF—lymph node—colon cancer	0.00179	0.0166	CbGeAlD
Bismuth Subsalicylate—Lung disorder—Irinotecan—colon cancer	0.00177	0.0273	CcSEcCtD
Bismuth Subsalicylate—Heartburn—Fluorouracil—colon cancer	0.00175	0.0269	CcSEcCtD
Bismuth Subsalicylate—Venous thrombosis—Capecitabine—colon cancer	0.00156	0.024	CcSEcCtD
Bismuth Subsalicylate—Stinging—Fluorouracil—colon cancer	0.00148	0.0229	CcSEcCtD
Bismuth Subsalicylate—Extravasation—Vincristine—colon cancer	0.00148	0.0228	CcSEcCtD
Bismuth Subsalicylate—Gastric ulcer—Capecitabine—colon cancer	0.00145	0.0223	CcSEcCtD
Bismuth Subsalicylate—Extravasation—Irinotecan—colon cancer	0.00144	0.0222	CcSEcCtD
Bismuth Subsalicylate—PTGS2—embryo—colon cancer	0.00143	0.0132	CbGeAlD
Bismuth Subsalicylate—Extravasation—Fluorouracil—colon cancer	0.00138	0.0212	CcSEcCtD
Bismuth Subsalicylate—PTGS1—epithelium—colon cancer	0.00122	0.0113	CbGeAlD
Bismuth Subsalicylate—ALB—liver—colon cancer	0.00122	0.0112	CbGeAlD
Bismuth Subsalicylate—PTGS1—smooth muscle tissue—colon cancer	0.00118	0.0109	CbGeAlD
Bismuth Subsalicylate—PTGS2—epithelium—colon cancer	0.00117	0.0108	CbGeAlD
Bismuth Subsalicylate—PTGS1—renal system—colon cancer	0.00114	0.0105	CbGeAlD
Bismuth Subsalicylate—PTGS2—smooth muscle tissue—colon cancer	0.00113	0.0104	CbGeAlD
Bismuth Subsalicylate—Oesophagitis—Fluorouracil—colon cancer	0.0011	0.0169	CcSEcCtD
Bismuth Subsalicylate—PTGS2—renal system—colon cancer	0.00109	0.01	CbGeAlD
Bismuth Subsalicylate—Deafness—Vincristine—colon cancer	0.00105	0.0161	CcSEcCtD
Bismuth Subsalicylate—Hyponatraemia—Vincristine—colon cancer	0.000939	0.0145	CcSEcCtD
Bismuth Subsalicylate—ALB—lymph node—colon cancer	0.000934	0.00861	CbGeAlD
Bismuth Subsalicylate—PTGS1—digestive system—colon cancer	0.000932	0.00859	CbGeAlD
Bismuth Subsalicylate—Hyponatraemia—Irinotecan—colon cancer	0.000915	0.0141	CcSEcCtD
Bismuth Subsalicylate—PTGS2—lymphoid tissue—colon cancer	0.000902	0.00831	CbGeAlD
Bismuth Subsalicylate—Burning sensation—Methotrexate—colon cancer	0.0009	0.0139	CcSEcCtD
Bismuth Subsalicylate—PTGS2—digestive system—colon cancer	0.000891	0.00821	CbGeAlD
Bismuth Subsalicylate—Lethargy—Fluorouracil—colon cancer	0.00089	0.0137	CcSEcCtD
Bismuth Subsalicylate—Lung disorder—Methotrexate—colon cancer	0.000883	0.0136	CcSEcCtD
Bismuth Subsalicylate—Hearing impaired—Capecitabine—colon cancer	0.000882	0.0136	CcSEcCtD
Bismuth Subsalicylate—PTGS1—vagina—colon cancer	0.000823	0.00759	CbGeAlD
Bismuth Subsalicylate—PTGS2—bone marrow—colon cancer	0.000821	0.00757	CbGeAlD
Bismuth Subsalicylate—Skin exfoliation—Capecitabine—colon cancer	0.000802	0.0124	CcSEcCtD
Bismuth Subsalicylate—PTGS2—vagina—colon cancer	0.000786	0.00725	CbGeAlD
Bismuth Subsalicylate—Oesophagitis—Capecitabine—colon cancer	0.000768	0.0118	CcSEcCtD
Bismuth Subsalicylate—Ecchymosis—Capecitabine—colon cancer	0.000759	0.0117	CcSEcCtD
Bismuth Subsalicylate—Extravasation—Methotrexate—colon cancer	0.000717	0.011	CcSEcCtD
Bismuth Subsalicylate—Phlebitis—Capecitabine—colon cancer	0.000708	0.0109	CcSEcCtD
Bismuth Subsalicylate—Deafness—Capecitabine—colon cancer	0.000682	0.0105	CcSEcCtD
Bismuth Subsalicylate—PTGS2—liver—colon cancer	0.000664	0.00612	CbGeAlD
Bismuth Subsalicylate—Hallucination—Vincristine—colon cancer	0.000644	0.00993	CcSEcCtD
Bismuth Subsalicylate—Epistaxis—Fluorouracil—colon cancer	0.000634	0.00978	CcSEcCtD
Bismuth Subsalicylate—Lethargy—Capecitabine—colon cancer	0.000622	0.00959	CcSEcCtD
Bismuth Subsalicylate—Hyponatraemia—Capecitabine—colon cancer	0.000612	0.00944	CcSEcCtD
Bismuth Subsalicylate—Skin exfoliation—Methotrexate—colon cancer	0.000597	0.0092	CcSEcCtD
Bismuth Subsalicylate—Ecchymosis—Methotrexate—colon cancer	0.000565	0.00871	CcSEcCtD
Bismuth Subsalicylate—Abdominal pain upper—Capecitabine—colon cancer	0.000557	0.00858	CcSEcCtD
Bismuth Subsalicylate—PTGS1—lymph node—colon cancer	0.000532	0.00491	CbGeAlD
Bismuth Subsalicylate—Asthma—Capecitabine—colon cancer	0.000527	0.00812	CcSEcCtD
Bismuth Subsalicylate—Erythema—Fluorouracil—colon cancer	0.000525	0.0081	CcSEcCtD
Bismuth Subsalicylate—PTGS2—lymph node—colon cancer	0.000509	0.00469	CbGeAlD
Bismuth Subsalicylate—Abdominal discomfort—Capecitabine—colon cancer	0.000505	0.00779	CcSEcCtD
Bismuth Subsalicylate—Weight increased—Capecitabine—colon cancer	0.00048	0.00739	CcSEcCtD
Bismuth Subsalicylate—Lethargy—Methotrexate—colon cancer	0.000463	0.00714	CcSEcCtD
Bismuth Subsalicylate—Oedema—Vincristine—colon cancer	0.00046	0.00709	CcSEcCtD
Bismuth Subsalicylate—Infection—Vincristine—colon cancer	0.000457	0.00704	CcSEcCtD
Bismuth Subsalicylate—Confusional state—Irinotecan—colon cancer	0.000451	0.00696	CcSEcCtD
Bismuth Subsalicylate—Oedema—Irinotecan—colon cancer	0.000448	0.0069	CcSEcCtD
Bismuth Subsalicylate—Infection—Irinotecan—colon cancer	0.000445	0.00686	CcSEcCtD
Bismuth Subsalicylate—Epistaxis—Capecitabine—colon cancer	0.000443	0.00683	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Vincristine—colon cancer	0.000438	0.00676	CcSEcCtD
Bismuth Subsalicylate—Confusional state—Fluorouracil—colon cancer	0.000432	0.00667	CcSEcCtD
Bismuth Subsalicylate—Oedema—Fluorouracil—colon cancer	0.000429	0.00661	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Irinotecan—colon cancer	0.000427	0.00658	CcSEcCtD
Bismuth Subsalicylate—Infection—Fluorouracil—colon cancer	0.000426	0.00657	CcSEcCtD
Bismuth Subsalicylate—Hepatitis—Capecitabine—colon cancer	0.000422	0.0065	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Fluorouracil—colon cancer	0.000409	0.0063	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Vincristine—colon cancer	0.0004	0.00616	CcSEcCtD
Bismuth Subsalicylate—Erythema multiforme—Capecitabine—colon cancer	0.000399	0.00615	CcSEcCtD
Bismuth Subsalicylate—Somnolence—Irinotecan—colon cancer	0.000398	0.00614	CcSEcCtD
Bismuth Subsalicylate—TF—HIF-1-alpha transcription factor network—HNF4A—colon cancer	0.000398	0.0719	CbGpPWpGaD
Bismuth Subsalicylate—Dyspepsia—Irinotecan—colon cancer	0.000394	0.00608	CcSEcCtD
Bismuth Subsalicylate—Tinnitus—Capecitabine—colon cancer	0.000393	0.00606	CcSEcCtD
Bismuth Subsalicylate—Pain—Vincristine—colon cancer	0.000393	0.00606	CcSEcCtD
Bismuth Subsalicylate—Constipation—Vincristine—colon cancer	0.000393	0.00606	CcSEcCtD
Bismuth Subsalicylate—Asthma—Methotrexate—colon cancer	0.000392	0.00605	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Irinotecan—colon cancer	0.000389	0.006	CcSEcCtD
Bismuth Subsalicylate—Constipation—Irinotecan—colon cancer	0.000383	0.0059	CcSEcCtD
Bismuth Subsalicylate—Pain—Irinotecan—colon cancer	0.000383	0.0059	CcSEcCtD
Bismuth Subsalicylate—Somnolence—Fluorouracil—colon cancer	0.000381	0.00588	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Fluorouracil—colon cancer	0.000377	0.00582	CcSEcCtD
Bismuth Subsalicylate—Abdominal discomfort—Methotrexate—colon cancer	0.000376	0.0058	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Fluorouracil—colon cancer	0.000373	0.00575	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Irinotecan—colon cancer	0.000369	0.00569	CcSEcCtD
Bismuth Subsalicylate—Erythema—Capecitabine—colon cancer	0.000367	0.00566	CcSEcCtD
Bismuth Subsalicylate—Pain—Fluorouracil—colon cancer	0.000367	0.00565	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Vincristine—colon cancer	0.000363	0.0056	CcSEcCtD
Bismuth Subsalicylate—Dysgeusia—Capecitabine—colon cancer	0.00036	0.00554	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Irinotecan—colon cancer	0.000354	0.00546	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Fluorouracil—colon cancer	0.000353	0.00545	CcSEcCtD
Bismuth Subsalicylate—Drowsiness—Methotrexate—colon cancer	0.00035	0.00539	CcSEcCtD
Bismuth Subsalicylate—Urticaria—Fluorouracil—colon cancer	0.000341	0.00525	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Fluorouracil—colon cancer	0.000339	0.00523	CcSEcCtD
Bismuth Subsalicylate—Epistaxis—Methotrexate—colon cancer	0.00033	0.00509	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Vincristine—colon cancer	0.000315	0.00485	CcSEcCtD
Bismuth Subsalicylate—Hepatitis—Methotrexate—colon cancer	0.000314	0.00484	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Irinotecan—colon cancer	0.000306	0.00472	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Vincristine—colon cancer	0.000304	0.00469	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Fluorouracil—colon cancer	0.000303	0.00468	CcSEcCtD
Bismuth Subsalicylate—Confusional state—Capecitabine—colon cancer	0.000302	0.00466	CcSEcCtD
Bismuth Subsalicylate—Oedema—Capecitabine—colon cancer	0.0003	0.00462	CcSEcCtD
Bismuth Subsalicylate—Infection—Capecitabine—colon cancer	0.000298	0.00459	CcSEcCtD
Bismuth Subsalicylate—Erythema multiforme—Methotrexate—colon cancer	0.000297	0.00458	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Irinotecan—colon cancer	0.000296	0.00456	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Fluorouracil—colon cancer	0.000293	0.00452	CcSEcCtD
Bismuth Subsalicylate—Tinnitus—Methotrexate—colon cancer	0.000293	0.00451	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Vincristine—colon cancer	0.000292	0.00451	CcSEcCtD
Bismuth Subsalicylate—Rash—Vincristine—colon cancer	0.00029	0.00447	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Vincristine—colon cancer	0.00029	0.00446	CcSEcCtD
Bismuth Subsalicylate—Headache—Vincristine—colon cancer	0.000288	0.00444	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Capecitabine—colon cancer	0.000286	0.0044	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Irinotecan—colon cancer	0.000285	0.00439	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Fluorouracil—colon cancer	0.000284	0.00437	CcSEcCtD
Bismuth Subsalicylate—Rash—Irinotecan—colon cancer	0.000282	0.00435	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Irinotecan—colon cancer	0.000282	0.00435	CcSEcCtD
Bismuth Subsalicylate—Headache—Irinotecan—colon cancer	0.00028	0.00432	CcSEcCtD
Bismuth Subsalicylate—Erythema—Methotrexate—colon cancer	0.000273	0.00421	CcSEcCtD
Bismuth Subsalicylate—Nausea—Vincristine—colon cancer	0.000273	0.00421	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Fluorouracil—colon cancer	0.000273	0.0042	CcSEcCtD
Bismuth Subsalicylate—Rash—Fluorouracil—colon cancer	0.00027	0.00417	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Fluorouracil—colon cancer	0.00027	0.00416	CcSEcCtD
Bismuth Subsalicylate—Headache—Fluorouracil—colon cancer	0.000269	0.00414	CcSEcCtD
Bismuth Subsalicylate—Dysgeusia—Methotrexate—colon cancer	0.000268	0.00413	CcSEcCtD
Bismuth Subsalicylate—Nausea—Irinotecan—colon cancer	0.000266	0.0041	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Capecitabine—colon cancer	0.000264	0.00407	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Capecitabine—colon cancer	0.000261	0.00402	CcSEcCtD
Bismuth Subsalicylate—Pain—Capecitabine—colon cancer	0.000256	0.00395	CcSEcCtD
Bismuth Subsalicylate—Constipation—Capecitabine—colon cancer	0.000256	0.00395	CcSEcCtD
Bismuth Subsalicylate—Nausea—Fluorouracil—colon cancer	0.000255	0.00393	CcSEcCtD
Bismuth Subsalicylate—TF—HIF-1-alpha transcription factor network—ABCB1—colon cancer	0.000248	0.0449	CbGpPWpGaD
Bismuth Subsalicylate—Feeling abnormal—Capecitabine—colon cancer	0.000247	0.00381	CcSEcCtD
Bismuth Subsalicylate—Urticaria—Capecitabine—colon cancer	0.000238	0.00367	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Capecitabine—colon cancer	0.000237	0.00365	CcSEcCtD
Bismuth Subsalicylate—Confusional state—Methotrexate—colon cancer	0.000225	0.00347	CcSEcCtD
Bismuth Subsalicylate—Infection—Methotrexate—colon cancer	0.000222	0.00342	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Methotrexate—colon cancer	0.000213	0.00328	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Capecitabine—colon cancer	0.000212	0.00327	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Capecitabine—colon cancer	0.000205	0.00316	CcSEcCtD
Bismuth Subsalicylate—Somnolence—Methotrexate—colon cancer	0.000198	0.00306	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Capecitabine—colon cancer	0.000198	0.00305	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Methotrexate—colon cancer	0.000196	0.00303	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Methotrexate—colon cancer	0.000194	0.00299	CcSEcCtD
Bismuth Subsalicylate—Pain—Methotrexate—colon cancer	0.000191	0.00294	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Capecitabine—colon cancer	0.000191	0.00294	CcSEcCtD
Bismuth Subsalicylate—Rash—Capecitabine—colon cancer	0.000189	0.00291	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Capecitabine—colon cancer	0.000189	0.00291	CcSEcCtD
Bismuth Subsalicylate—Headache—Capecitabine—colon cancer	0.000188	0.00289	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Methotrexate—colon cancer	0.000184	0.00283	CcSEcCtD
Bismuth Subsalicylate—PTGS1—Overview of nanoparticle effects—BAX—colon cancer	0.00018	0.0326	CbGpPWpGaD
Bismuth Subsalicylate—Nausea—Capecitabine—colon cancer	0.000178	0.00274	CcSEcCtD
Bismuth Subsalicylate—Urticaria—Methotrexate—colon cancer	0.000177	0.00273	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Methotrexate—colon cancer	0.000176	0.00272	CcSEcCtD
Bismuth Subsalicylate—TF—EPHB forward signaling—SRC—colon cancer	0.000167	0.0303	CbGpPWpGaD
Bismuth Subsalicylate—TF—EPHB forward signaling—NRAS—colon cancer	0.000161	0.0291	CbGpPWpGaD
Bismuth Subsalicylate—Pruritus—Methotrexate—colon cancer	0.000158	0.00243	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Methotrexate—colon cancer	0.000153	0.00235	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Methotrexate—colon cancer	0.000148	0.00227	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Overview of nanoparticle effects—BAX—colon cancer	0.000143	0.0259	CbGpPWpGaD
Bismuth Subsalicylate—Vomiting—Methotrexate—colon cancer	0.000142	0.00219	CcSEcCtD
Bismuth Subsalicylate—Rash—Methotrexate—colon cancer	0.000141	0.00217	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Methotrexate—colon cancer	0.000141	0.00217	CcSEcCtD
Bismuth Subsalicylate—Headache—Methotrexate—colon cancer	0.00014	0.00215	CcSEcCtD
Bismuth Subsalicylate—TF—EPHB forward signaling—KRAS—colon cancer	0.000139	0.0251	CbGpPWpGaD
Bismuth Subsalicylate—TF—Differentiation Pathway—VEGFA—colon cancer	0.000138	0.025	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—colon cancer	0.000133	0.0241	CbGpPWpGaD
Bismuth Subsalicylate—Nausea—Methotrexate—colon cancer	0.000133	0.00204	CcSEcCtD
Bismuth Subsalicylate—TF—EPHB forward signaling—PIK3CA—colon cancer	0.000127	0.023	CbGpPWpGaD
Bismuth Subsalicylate—TF—Differentiation Pathway—TGFB1—colon cancer	0.000127	0.0229	CbGpPWpGaD
Bismuth Subsalicylate—TF—EPHB forward signaling—HRAS—colon cancer	0.000118	0.0213	CbGpPWpGaD
Bismuth Subsalicylate—TF—HIF-1-alpha transcription factor network—EP300—colon cancer	0.000113	0.0204	CbGpPWpGaD
Bismuth Subsalicylate—TF—HIF-1-alpha transcription factor network—VEGFA—colon cancer	0.000107	0.0193	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Overview of nanoparticle effects—PTGS2—colon cancer	0.000104	0.0189	CbGpPWpGaD
Bismuth Subsalicylate—ALB—FOXA2 and FOXA3 transcription factor networks—HNF4A—colon cancer	0.0001	0.0181	CbGpPWpGaD
Bismuth Subsalicylate—TF—Platelet degranulation—VEGFA—colon cancer	9.17e-05	0.0166	CbGpPWpGaD
Bismuth Subsalicylate—TF—Response to elevated platelet cytosolic Ca2+—VEGFA—colon cancer	8.74e-05	0.0158	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Eicosanoid Synthesis—PTGS2—colon cancer	8.65e-05	0.0157	CbGpPWpGaD
Bismuth Subsalicylate—TF—Platelet degranulation—TGFB1—colon cancer	8.42e-05	0.0152	CbGpPWpGaD
Bismuth Subsalicylate—TF—Response to elevated platelet cytosolic Ca2+—TGFB1—colon cancer	8.02e-05	0.0145	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—colon cancer	7.48e-05	0.0135	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—colon cancer	7.24e-05	0.0131	CbGpPWpGaD
Bismuth Subsalicylate—TF—HIF-1-alpha transcription factor network—AKT1—colon cancer	6.82e-05	0.0123	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—TOP1—colon cancer	6.66e-05	0.012	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—S1P1 pathway—VEGFA—colon cancer	6.52e-05	0.0118	CbGpPWpGaD
Bismuth Subsalicylate—TF—SIDS Susceptibility Pathways—CASP3—colon cancer	6.33e-05	0.0115	CbGpPWpGaD
Bismuth Subsalicylate—TF—SIDS Susceptibility Pathways—CTNNB1—colon cancer	6.11e-05	0.011	CbGpPWpGaD
Bismuth Subsalicylate—TF—SIDS Susceptibility Pathways—EP300—colon cancer	5.68e-05	0.0103	CbGpPWpGaD
Bismuth Subsalicylate—TF—SIDS Susceptibility Pathways—VEGFA—colon cancer	5.37e-05	0.00972	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—colon cancer	4.85e-05	0.00878	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Arachidonic acid metabolism—PTGS2—colon cancer	4.81e-05	0.0087	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—DCC—colon cancer	4.55e-05	0.00822	CbGpPWpGaD
Bismuth Subsalicylate—TF—Transmembrane transport of small molecules—ABCB1—colon cancer	4.21e-05	0.00762	CbGpPWpGaD
Bismuth Subsalicylate—TF—Platelet activation, signaling and aggregation—SRC—colon cancer	4.18e-05	0.00755	CbGpPWpGaD
Bismuth Subsalicylate—TF—Platelet activation, signaling and aggregation—VEGFA—colon cancer	4.07e-05	0.00736	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—HNF4A—colon cancer	3.83e-05	0.00692	CbGpPWpGaD
Bismuth Subsalicylate—TF—Platelet activation, signaling and aggregation—TGFB1—colon cancer	3.73e-05	0.00675	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—CDKN1A—colon cancer	3.57e-05	0.00645	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CASP3—colon cancer	3.54e-05	0.00641	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—CA7—colon cancer	3.49e-05	0.00632	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—EP300—colon cancer	3.39e-05	0.00614	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—SRC—colon cancer	3.3e-05	0.00597	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—colon cancer	3.22e-05	0.00582	CbGpPWpGaD
Bismuth Subsalicylate—TF—Platelet activation, signaling and aggregation—PIK3CA—colon cancer	3.18e-05	0.00575	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—NRAS—colon cancer	3.18e-05	0.00574	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Selenium Micronutrient Network—PTGS2—colon cancer	3.06e-05	0.00554	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—BUB1B—colon cancer	3.06e-05	0.00553	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—colon cancer	3.02e-05	0.00547	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—MYC—colon cancer	2.96e-05	0.00535	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—EGFR—colon cancer	2.89e-05	0.00523	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—CA7—colon cancer	2.77e-05	0.00502	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—KRAS—colon cancer	2.73e-05	0.00494	CbGpPWpGaD
Bismuth Subsalicylate—TF—Platelet activation, signaling and aggregation—AKT1—colon cancer	2.6e-05	0.00469	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—ABCB1—colon cancer	2.39e-05	0.00432	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—TYMS—colon cancer	2.35e-05	0.00424	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—HRAS—colon cancer	2.32e-05	0.0042	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—CCND1—colon cancer	2.28e-05	0.00412	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—BAX—colon cancer	2.26e-05	0.00409	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—CA7—colon cancer	2.24e-05	0.00406	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—EP300—colon cancer	2.21e-05	0.004	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—CDKN1A—colon cancer	2.2e-05	0.00399	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—SRC—colon cancer	2.15e-05	0.00389	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—ODC1—colon cancer	2.12e-05	0.00383	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—CHST5—colon cancer	2.12e-05	0.00383	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—EP300—colon cancer	2.1e-05	0.00379	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—VEGFA—colon cancer	2.1e-05	0.00379	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—NRAS—colon cancer	2.07e-05	0.00375	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—LGR5—colon cancer	2.01e-05	0.00363	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—CHST5—colon cancer	2.01e-05	0.00363	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Selenium Micronutrient Network—PTGS2—colon cancer	1.97e-05	0.00355	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—NRAS—colon cancer	1.96e-05	0.00355	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—TGFB1—colon cancer	1.92e-05	0.00348	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—MYC—colon cancer	1.83e-05	0.00331	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—CASP3—colon cancer	1.78e-05	0.00323	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—KRAS—colon cancer	1.78e-05	0.00322	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—CCND1—colon cancer	1.74e-05	0.00314	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—APC—colon cancer	1.72e-05	0.00311	CbGpPWpGaD
Bismuth Subsalicylate—ALB—FOXA2 and FOXA3 transcription factor networks—AKT1—colon cancer	1.72e-05	0.00311	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—KRAS—colon cancer	1.69e-05	0.00305	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—CHST5—colon cancer	1.68e-05	0.00304	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—ODC1—colon cancer	1.68e-05	0.00304	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet degranulation—VEGFA—colon cancer	1.67e-05	0.00302	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—PIK3CA—colon cancer	1.64e-05	0.00296	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—colon cancer	1.59e-05	0.00288	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—TP53—colon cancer	1.58e-05	0.00287	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet degranulation—TGFB1—colon cancer	1.53e-05	0.00277	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—HRAS—colon cancer	1.52e-05	0.00274	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Folate Metabolism—TP53—colon cancer	1.47e-05	0.00266	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—colon cancer	1.46e-05	0.00264	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—AXIN2—colon cancer	1.44e-05	0.00261	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—HRAS—colon cancer	1.44e-05	0.0026	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—MYC—colon cancer	1.39e-05	0.00252	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—TGFB1—colon cancer	1.39e-05	0.00251	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—EGFR—colon cancer	1.36e-05	0.00246	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—ODC1—colon cancer	1.36e-05	0.00246	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—CHST5—colon cancer	1.36e-05	0.00246	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—AKT1—colon cancer	1.34e-05	0.00242	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—colon cancer	1.21e-05	0.00219	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—colon cancer	1.18e-05	0.00214	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—colon cancer	1.17e-05	0.00212	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—TP53—colon cancer	1.14e-05	0.00207	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—colon cancer	1.14e-05	0.00207	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—colon cancer	1.09e-05	0.00197	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—SRC—colon cancer	1.06e-05	0.00191	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—colon cancer	1.03e-05	0.00186	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	9.47e-06	0.00171	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	9.45e-06	0.00171	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	9.26e-06	0.00168	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	8.75e-06	0.00158	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—PPARG—colon cancer	8.74e-06	0.00158	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	8.04e-06	0.00145	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	7.78e-06	0.00141	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Transmembrane transport of small molecules—ABCB1—colon cancer	7.67e-06	0.00139	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—SRC—colon cancer	7.61e-06	0.00138	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—VEGFA—colon cancer	7.41e-06	0.00134	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—PPARG—colon cancer	6.94e-06	0.00125	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	6.87e-06	0.00124	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—TGFB1—colon cancer	6.8e-06	0.00123	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	6.57e-06	0.00119	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—PIK3CA—colon cancer	5.79e-06	0.00105	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—EP300—colon cancer	5.72e-06	0.00103	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—PPARG—colon cancer	5.61e-06	0.00102	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—ABCB1—colon cancer	5.59e-06	0.00101	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—TYMS—colon cancer	5.49e-06	0.000994	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—AKT1—colon cancer	4.73e-06	0.000855	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—EP300—colon cancer	4.54e-06	0.000821	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—ABCB1—colon cancer	4.44e-06	0.000803	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	4.42e-06	0.000799	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—TYMS—colon cancer	4.36e-06	0.000789	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	4.23e-06	0.000765	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—FGFR3—colon cancer	4.16e-06	0.000753	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—EP300—colon cancer	4.03e-06	0.00073	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—SRC—colon cancer	3.92e-06	0.000709	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—PPARG—colon cancer	3.89e-06	0.000704	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—APC—colon cancer	3.82e-06	0.000691	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—VEGFA—colon cancer	3.82e-06	0.000691	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—NRAS—colon cancer	3.77e-06	0.000683	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—EP300—colon cancer	3.67e-06	0.000664	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—BRAF—colon cancer	3.59e-06	0.00065	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—ABCB1—colon cancer	3.59e-06	0.00065	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—TYMS—colon cancer	3.53e-06	0.000638	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—TGFB1—colon cancer	3.51e-06	0.000634	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	3.36e-06	0.000607	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—KRAS—colon cancer	3.25e-06	0.000587	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—PPARG—colon cancer	3.09e-06	0.000559	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—PTGS2—colon cancer	3.06e-06	0.000554	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—PIK3CA—colon cancer	2.98e-06	0.00054	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—TP53—colon cancer	2.89e-06	0.000522	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—HRAS—colon cancer	2.76e-06	0.000499	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	2.72e-06	0.000491	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—CTNNB1—colon cancer	2.6e-06	0.00047	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—EP300—colon cancer	2.55e-06	0.000461	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—CDKN1A—colon cancer	2.54e-06	0.000459	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PPARG—colon cancer	2.5e-06	0.000452	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—AKT1—colon cancer	2.44e-06	0.000441	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—EP300—colon cancer	2.41e-06	0.000437	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—SRC—colon cancer	2.35e-06	0.000425	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—NRAS—colon cancer	2.26e-06	0.000408	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—MYC—colon cancer	2.1e-06	0.00038	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—TGFB1—colon cancer	2.1e-06	0.00038	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—EGFR—colon cancer	2.06e-06	0.000372	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—EP300—colon cancer	2.02e-06	0.000366	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PTGS2—colon cancer	1.97e-06	0.000356	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—KRAS—colon cancer	1.94e-06	0.000352	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—PIK3CA—colon cancer	1.88e-06	0.000341	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—PIK3CA—colon cancer	1.79e-06	0.000323	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—HRAS—colon cancer	1.65e-06	0.000299	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—EP300—colon cancer	1.64e-06	0.000296	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—AKT1—colon cancer	1.54e-06	0.000278	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—PIK3CA—colon cancer	1.5e-06	0.00027	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—AKT1—colon cancer	1.46e-06	0.000264	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—AKT1—colon cancer	1.22e-06	0.000221	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PIK3CA—colon cancer	1.21e-06	0.000219	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—AKT1—colon cancer	9.88e-07	0.000179	CbGpPWpGaD
